BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm 2014;36:1115-25. [DOI: 10.1007/s11096-014-0023-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Koibuchi K, Miyagi M, Arai T, Aoki T, Aikawa A, Sakai K. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis: Hb maintenance by ESAs in predialysis. Nephrology 2015;20:22-8. [DOI: 10.1111/nep.12641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. J Nephrol 2018;31:321-32. [DOI: 10.1007/s40620-017-0419-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
3 Arantes LH Jr, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, Scotte F, Wish J. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol 2018;129:79-90. [PMID: 30097240 DOI: 10.1016/j.critrevonc.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Tsuruya K, Uemura Y, Hirakata H, Kitazono T, Tsubakihara Y, Suzuki M, Ohashi Y. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton) 2017;22:769-75. [PMID: 27312361 DOI: 10.1111/nep.12842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Schmid H. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Rev Hematol 2016;9:5-20. [PMID: 26573694 DOI: 10.1586/17474086.2016.1112734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 MacLure K, Paudyal V, Stewart D. Reviewing the literature, how systematic is systematic? Int J Clin Pharm 2016;38:685-94. [PMID: 27048436 DOI: 10.1007/s11096-016-0288-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Menger MM, Nalbach L, Wrublewsky S, Glanemann M, Gu Y, Laschke MW, Menger MD, Ampofo E. Darbepoetin-α increases the blood volume flow in transplanted pancreatic islets in mice. Acta Diabetol 2020;57:1009-18. [PMID: 32221724 DOI: 10.1007/s00592-020-01512-w] [Reference Citation Analysis]